994 related articles for article (PubMed ID: 21694464)
1. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
2. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms.
Zhou M; Roma A; Magi-Galluzzi C
Clin Lab Med; 2005 Jun; 25(2):247-57. PubMed ID: 15848735
[TBL] [Abstract][Full Text] [Related]
3. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
4. Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.
Mai KT; Alhalouly T; Lamba M; Yazdi HM; Stinson WA
Diagn Cytopathol; 2003 Feb; 28(2):66-70. PubMed ID: 12561022
[TBL] [Abstract][Full Text] [Related]
5. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
[TBL] [Abstract][Full Text] [Related]
7. CD70: a new tumor specific biomarker for renal cell carcinoma.
Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
[TBL] [Abstract][Full Text] [Related]
8. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas.
Allory Y; Matsuoka Y; Bazille C; Christensen EI; Ronco P; Debiec H
Clin Cancer Res; 2005 Feb; 11(3):1190-7. PubMed ID: 15709188
[TBL] [Abstract][Full Text] [Related]
9. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.
Margulis V; Tamboli P; Matin SF; Swanson DA; Wood CG
Cancer; 2008 Apr; 112(7):1480-8. PubMed ID: 18240184
[TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other.
Tollefson MK; Thompson RH; Sheinin Y; Lohse CM; Cheville JC; Leibovich BC; Kwon ED
Cancer; 2007 Aug; 110(4):783-90. PubMed ID: 17594714
[TBL] [Abstract][Full Text] [Related]
13. Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.
Bierer S; Herrmann E; Köpke T; Neumann J; Eltze E; Hertle L; Wülfing C
Oncol Rep; 2008 Oct; 20(4):721-5. PubMed ID: 18813809
[TBL] [Abstract][Full Text] [Related]
14. The distinction of clear cell carcinoma of the female genital tract, clear cell renal cell carcinoma, and translocation-associated renal cell carcinoma: an immunohistochemical study using tissue microarray.
He H; Zhou GX; Zhou M; Chen L
Int J Gynecol Pathol; 2011 Sep; 30(5):425-30. PubMed ID: 21804394
[TBL] [Abstract][Full Text] [Related]
15. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer.
Chandarana H; Rosenkrantz AB; Mussi TC; Kim S; Ahmad AA; Raj SD; McMenamy J; Melamed J; Babb JS; Kiefer B; Kiraly AP
Radiology; 2012 Dec; 265(3):790-8. PubMed ID: 23175544
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic molecular markers in renal cell carcinoma.
Tunuguntla HS; Jorda M
J Urol; 2008 Jun; 179(6):2096-102. PubMed ID: 18423738
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
[TBL] [Abstract][Full Text] [Related]
19. Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas.
Fritzsche FR; Oelrich B; Johannsen M; Kristiansen I; Moch H; Jung K; Kristiansen G
Clin Cancer Res; 2008 Nov; 14(21):7035-42. PubMed ID: 18981000
[TBL] [Abstract][Full Text] [Related]
20. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
